Author Archive: Cartier Esham

Cartier Esham

Cartier Esham serves as Executive Vice President for Emerging Companies at the Biotechnology Industry Organization (BIO). In this role, Dr. Esham manages and directs BIO’s policy development, advocacy, research and educational initiatives for BIO’s emerging companies, which comprise approximately 90percent of BIO’s membership.

Latest Posts

Roadblocks and Red Tape Block Search for Cures

scientist-eyedropper

Since its passage more than two years ago, the JOBS Act has spurred more than 110 biotech IPOs. And now the SEC is in the process of finalizing another important piece of the law that could further encourage biotech capital formation. The JOBS Act directs the SEC to raise the offering ceiling under Regulation A – a securities law exemption that allows companies to raise public capital with a reduced reporting burden – from $5 Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,